Regeneron Pharmaceuticals (NQ:REGN)

Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss Market ↗

October 19, 2026

Is this company the biggest dark horse in the chronic weight management space?

Regeneron's biggest growth driver still has plenty of fuel left in the tank.

Forget Eylea: Regeneron's Real Value May Be Hiding in Its Dupixent Profit Share ↗

October 17, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount ↗

September 09, 2026

Via Chartmill

Q2 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks

October 14, 2026

As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the biotechnology industry, including Regeneron (NASDAQ:REGN) and...

What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all...

Topics Artificial Intelligence

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Discover which S&P500 stocks are making waves on Monday. ↗

October 12, 2026

Via Chartmill

Why Regeneron (REGN) Stock Is Trading Lower Today

October 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...

Which S&P500 stocks are moving on Thursday? ↗

October 01, 2026

Via Chartmill

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗

October 01, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

Topics ETFs

Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment

September 30, 2026

The healthcare company will release its third-quarter results next month.

Topics Artificial Intelligence

Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗

September 28, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm

September 28, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives highlighted continued growth across key marketed products, a broad late-stage pipeline and an ongoing focus on science-driven business development...

Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗

September 23, 2026

The past couple of years have been challenging for the company, but there is a light at the end of the tunnel.

Topics ETFs

Is Regeneron Stock a Bargain Below $800? ↗

September 22, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Topics Intellectual Property

1 S&P 500 Stock Worth Your Attention and 2 We Ignore

September 22, 2026

Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗

Topics Stocks

September 15, 2026

Novo Nordisk is bigger and more profitable on paper, but pricing pressure, reduced Medicaid coverage, and intensifying competition are creating headwinds that Regeneron simply does not face right now.

Regeneron Pharmaceuticals (NASDAQ:REGN) outlined growth opportunities for Dupixent, pipeline catalysts for cemdisiran and continued commercial momentum for EYLEA HD during the Morgan Stanley Global...

Topics Regulatory Compliance

Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗

September 14, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) executives outlined plans for continued growth across its commercial portfolio, upcoming regulatory milestones and pipeline programs during a Wells Fargo...

Topics Intellectual Property

Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗

September 12, 2026

Although Regeneron (currently trading at $845.04 per share) has gained 8.1% over the last six months, it has trailed the S&P 500’s 13.6% return during that p...

Topics ETFs

3 Reasons to Avoid REGN and 1 Stock to Buy Instead

September 08, 2026

They could both outperform the market over the medium term, but one appears to have a clear edge.

Topics Stocks

Vertex vs. Regeneron: Which Biotech Giant Is the Better Buy Right Now? ↗

September 04, 2026

Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 15 Years ↗

Topics Intellectual Property

September 02, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 4.59% on an annualized basis producing an average annual return of 17.79%. Currently, Regeneron...

Via Benzinga

$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today ↗

August 24, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 6.17% on an annualized basis producing an average annual return of 19.2%. Currently, Regeneron...

Via Benzinga

Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks

August 17, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...

They are fairly risky, but their potential upside is massive.

Topics Artificial Intelligence

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗

August 14, 2026

They are way more than just GLP-1 stocks.

If You Invested $1000 In Regeneron Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

Topics Intellectual Property

August 14, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.69% on an annualized basis producing an average annual return of 22.03%. Currently, Regeneron...

Via Benzinga

The Top 5 Analyst Questions From Regeneron’s Q2 Earnings Call

August 06, 2026

Regeneron’s second quarter was marked by strong commercial execution and robust product demand, resulting in financial results that surpassed Wall Street’s e...

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t...

Topics Earnings

1 Value Stock with Promising Prospects and 2 We Avoid

August 04, 2026

Revenue surged 17% as Dupixent and EYLEA HD posted record sales.

Regeneron (REGN) Q2 2026 Earnings Call Transcript ↗

August 03, 2026